0001328143-21-000094.txt : 20211124
0001328143-21-000094.hdr.sgml : 20211124
20211124161116
ACCESSION NUMBER: 0001328143-21-000094
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211124
FILED AS OF DATE: 20211124
DATE AS OF CHANGE: 20211124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAHONEY DAVID L
CENTRAL INDEX KEY: 0001224091
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36399
FILM NUMBER: 211446564
MAIL ADDRESS:
STREET 1: SYMANTEC CORPORATION
STREET 2: 20330 STEVENS CREEK BLVD.
CITY: CUPERTINO
STATE: CA
ZIP: 95014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001328143
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 421560076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 510-450-3554
MAIL ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050524
4
1
wf-form4_163778824532046.xml
FORM 4
X0306
4
2021-11-24
1
0001328143
Adamas Pharmaceuticals Inc
ADMS
0001224091
MAHONEY DAVID L
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 1000
EMERYVILLE
CA
94608
1
0
0
0
Common Stock
2021-11-24
4
U
0
5000
D
0
D
Common Stock
2021-11-24
4
U
0
112781
D
0
I
David L. Mahoney & Winnifred C. Ellis 1998 Family Trust
Stock Option (Right to Buy)
4.8
2021-11-24
4
D
0
10000
D
2029-06-04
Common Stock
10000.0
0
D
Stock Option (Right to Buy)
6.08
2021-11-24
4
D
0
40000
D
2029-09-10
Common Stock
40000.0
0
D
Stock Option (Right to Buy)
2.7
2021-11-24
4
D
0
10000
D
2030-06-02
Common Stock
10000.0
0
D
Stock Option (Right to Buy)
5.21
2021-11-24
4
D
0
10000
D
2022-06-02
2031-06-01
Common Stock
10000.0
0
D
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
The stock option is fully vested and exercisable.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
$3.30 plus two CVRs per share underlying the stock option.
The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
$2.02 plus two CVRs per share underlying the stock option.
$5.40 plus two CVRs per share underlying the stock option.
$2.89 plus two CVRs per share underlying the stock option.
/s/ Brett White, Attorney-in-fact
2021-11-24